Scholarlink

Background <p>Despite its increasing prevalence, the economic impact of eosinophilic esophagitis (EoE) in Europe is understudied and direct economic costs remain unknown.</p> Objective <p>To assess contemporaneous direct medical costs during the first year after EoE diagnosis in Spain to identify key cost determinants and assess variables that could affect these costs.</p> Methods <p>Observational study of Spanish participants in the EUREOS EoE CONNECT registry with incident EoE in 2017–2018. We assessed average costs/year in Euros for endoscopic procedures, out-patient visits, medication, emergency room visits and hospitalizations, 2018 being our base year. Official regional tariffs were used to estimate direct costs from a healthcare provider perspective; official price lists were used for drug therapies. Cost differences and determinants were assessed with multivariate models.</p> Results <p>The mean annual direct cost of EoE per person among 302 patients (76.5% male, 77.5% adults) was €1,842.07 (SD €795.69). Endoscopic procedures accounted for 68% of this, followed by outpatient visits (15.9%) and drug prescriptions (10.8%). Cost was higher for pediatric compared to adult patients (€2,101.51 vs. €1,784.29, <i>p</i> &lt; 0.01), for those with higher EREFS score (€1,979.36 vs. €1,794.49; <i>p</i> &lt; 0.01), and in high-volume hospitals (€1,941.48 vs. €1,723.92; <i>p</i> = 0.02). Early response to first-line treatment reduced annual costs by –€368.95 (<i>p</i> &lt; 0.01), by avoiding further medical procedures.</p> Conclusion <p>First year after EoE diagnosis produces significant direct costs in Spain, mainly due to endoscopic procedures, which are reduced in early responders to first-line therapy. Research for non-invasive methods for EoE assessment and identifying predictors of response are, therefore, key.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Economic burden of eosinophilic esophagitis in the first year after diagnosis in Spain: A direct medical cost analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月18日

查看全文
  • Leticia Rodriguez-Alcolado,
  • Isaac Aranda-Reneo,
  • Sergio Casabona,
  • Isabel Pérez-Martínez,
  • Danila Guagnozzi,
  • Carolina Gutiérrez-Junquera,
  • Edurne Amorena,
  • Antonio Guardiola-Arévalo,
  • Luisa de la Peña-Negro,
  • Leonardo Blas Jhon,
  • Sandra López García-Dionisio,
  • Jennifer Fernández-Pacheco,
  • Jesús Barrio,
  • Sonia Fernández-Fernández,
  • Elena Betoré,
  • Susana de la Riva,
  • Carlos Teruel Sánchez-Vegazo,
  • Juan Armando Rodríguez-Oballe,
  • Juan Enrique Naves,
  • Juan K. Bisso-Zein,
  • Silvia Carrión,
  • Adolfo Suárez,
  • Ronald Llerena-Castro,
  • Alejandro García-Díaz,
  • Óscar Nantes-Castillejo,
  • Alicia Granja-Navacerrada,
  • Antonia Perelló,
  • Marta Álvarez-García,
  • Cecilio Santander,
  • Emilio J. Laserna-Mendieta,
  • Juan Oliva-Moreno,
  • Alfredo J. Lucendo

摘要

Background

Despite its increasing prevalence, the economic impact of eosinophilic esophagitis (EoE) in Europe is understudied and direct economic costs remain unknown.

Objective

To assess contemporaneous direct medical costs during the first year after EoE diagnosis in Spain to identify key cost determinants and assess variables that could affect these costs.

Methods

Observational study of Spanish participants in the EUREOS EoE CONNECT registry with incident EoE in 2017–2018. We assessed average costs/year in Euros for endoscopic procedures, out-patient visits, medication, emergency room visits and hospitalizations, 2018 being our base year. Official regional tariffs were used to estimate direct costs from a healthcare provider perspective; official price lists were used for drug therapies. Cost differences and determinants were assessed with multivariate models.

Results

The mean annual direct cost of EoE per person among 302 patients (76.5% male, 77.5% adults) was €1,842.07 (SD €795.69). Endoscopic procedures accounted for 68% of this, followed by outpatient visits (15.9%) and drug prescriptions (10.8%). Cost was higher for pediatric compared to adult patients (€2,101.51 vs. €1,784.29, p < 0.01), for those with higher EREFS score (€1,979.36 vs. €1,794.49; p < 0.01), and in high-volume hospitals (€1,941.48 vs. €1,723.92; p = 0.02). Early response to first-line treatment reduced annual costs by –€368.95 (p < 0.01), by avoiding further medical procedures.

Conclusion

First year after EoE diagnosis produces significant direct costs in Spain, mainly due to endoscopic procedures, which are reduced in early responders to first-line therapy. Research for non-invasive methods for EoE assessment and identifying predictors of response are, therefore, key.